Investments
Oct. 22, 2011
Big pharma willing to invest in early stage technology, survey says
Pharmaceutical and large biotechnology companies are paying less to partner with small biotech firms, but they're willing to invest in early stage technology again, according to a Campbell Alliance survey presented to Biocom in San Diego.




By Mandy Jackson
Daily Journal Staff Writer
Pharmaceutical and large biotechnology companies are paying less to partner with smaller biotech firms, but the good news is that they're willing to invest in early-stage technology again.
The Campbell Alliance, a pharmaceutical consulting firm, delivered that news in its annual Dealmakers' Intentions Survey, which was discussed by Southern California biotech executives on Thursday during a m...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In